# A Study of the Effect of SYN-010 on Subjects With IBS-C

> **NCT02495623** · PHASE2 · COMPLETED · sponsor: **Theriva Biologics, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Constipation (IBS-C)

## Interventions

- **DRUG:** SYN-010 21 mg
- **DRUG:** SYN-010 42 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02495623
- **Lead sponsor:** Theriva Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2015-10
- **Final completion:** 2015-11
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02495623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02495623, "A Study of the Effect of SYN-010 on Subjects With IBS-C". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02495623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*